- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears AI 'Contouring Assistant' in MRI-Guided Ultrasound Ablation Procedures
The artificial intelligence (AI)-powered module provides a prostate segmentation tool for MRI-guided transurethral ultrasound ablation (TULSA) procedures in patients with prostate cancer.
Reportedly built on over 24 million parameters drawn from nearly 7,500 training images, the artificial intelligence (AI) module Contouring Assistant has garnered 510(k) clearance from the Food and Drug Administration (FDA) for use in MRI-guided transurethral ultrasound ablation (TULSA) procedures in patients with prostate cancer.
Utilized in conjunction with Profound Medical’s TULSA-PRO system, the Contouring Assistant module offers machine learning-based segmentation of the prostate to facilitate targeted ablation of diseased tissue.
Utilized in conjunction with Profound Medical’s TULSA-PRO system (shown above), the recently FDA-cleared Contouring Assistant module provides machine-learning based prostate segmentation, which was found to be non-inferior to contouring done by leading prostate radiologists, according to Profound Medical, the manufacturer of the Contouring Assistant module. (Image courtesy of Profound Medical.)
Profound Medical noted that the Contouring Assistant module was developed with a reference standard that combined contours from leading prostate radiologists Steven Raman, M.D., Robert Princethal, M.D., and Edward Steiner, M.D. Subsequent research evaluating the stand-alone capability of Contouring Assistant in 100 prostate cancer cases found it was non-inferior to the aforementioned reference standard, according to Profound Medical.
The company also noted that additional testing of the Contouring Assistant module by three urologists demonstrated a 32 percent reduction in the time it took to complete prostate segmentation.
“ … (Contouring) Assistant not only allowed my esteemed urologist colleagues and I to approach the accuracy of an expert radiologist reader in our TULSA treatment designs, but also enabled us to reduce overall procedure times by one-third,” noted Preston Sprenkle, M.D., an associate professor of urology at the Yale School of Medicine in New Haven, Ct.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
